Chemotherapy Plus Venetoclax

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
508 patients (estimated)
Sponsors
MD Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Tags
BCL-2 Inhibitor, Chemotherapy, Kinase Inhibitor, Tyrosine Kinase (TK) Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1561
NCT Identifier
NCT02115295

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.